TEZSPIRE DIN 02529548
Health Canada record
| Active ingredient(s) | TEZEPELUMAB 110 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | R03DX11 TEZEPELUMAB |
| Original market date | 19-Oct-2022 |
| Current status date | 19-Oct-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
AstraZeneca Canada Inc. — licence 100421, currently licensed, last inspection rating C (2023-06-12).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TEZEPELUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02529556 | TEZSPIRE | ASTRAZENECA CANADA INC | Solution | TEZEPELUMAB 110 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 28666 | 2022-07-28 | New Drug Submission (NDS) |
International API supply for TEZEPELUMAB
1 active FDA Drug Master Files.
Request a quote for TEZSPIRE